Treatment of Subacute Cutaneous Lupus Erythematosus with Severe or Widespread Skin Lesions, Risk of Scarring, or Risk of Systemic Disease
When subacute cutaneous lupus erythematosus (SCLE) presents with severe or widespread skin involvement — or when there is a meaningful risk of scarring or progression toward systemic disease — a structured systemic management approach is warranted.
This protocol applies to patients with severe or widespread cutaneous lupus erythematosus skin lesions, those at risk of scarring, or those at risk of developing systemic lupus erythematosus. Antimalarials are recommended as first-line and long-term systemic treatment in this population. In the setting of severe or widespread active lesions, systemic corticosteroids are also recommended as first-line treatment in addition to antimalarials.
For patients in whom initial systemic therapy does not achieve adequate disease control, systemic retinoid therapy represents one recognised next-step option — typically used in addition to antimalarials. The complete protocol, including all treatment options, their sequencing, and monitoring requirements, is available via the full structured regimen.
References
- We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
- In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
- We recommend retinoids as second-line systemic treatment in selected CLE patients unresponsive to other treatments, preferably in addition to antimalarials.